|Alseres Pharmaceuticals, Inc.|
275 Grove Street
United States - Map
Alseres Pharmaceuticals, Inc., a biotechnology company, together with its subsidiaries, focuses on developing therapeutic and diagnostic products primarily for disorders in the central nervous system. The companys clinical product candidate, Altropane, is a molecular imaging program, which focuses on the diagnosis of Parkinsonian syndromes, including Parkinsons disease, and dementia with lewy bodies. It has a license agreement with Navidea Biopharmaceuticals, Inc. to research, develop, and commercialize Altropane, an Iodine-123 radiolabeled imaging agent for the diagnosis of Parkinsons disease and movement disorders. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.
|Mr. Peter G. Savas ,
Exec. Chairman, Chief Exec. Officer and Member of Fin. Committee
|Mr. Kenneth L. Rice Jr., J.D., LLM, MBA,
Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. & Admin., Sec. and In-House Counsel
|Mr. Sam Martin ,
Director of Fin. and Corp. Compliance
|Dr. Noel Cusack Ph.D.,
Sr. VP of Preclinical Devel.
|Dr. Mark R. Hurtt M.D.,
Chief Medical Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|